HHS Approval of Entities That Certify Medical Review Officers, 39763 [2018-17184]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 155 / Friday, August 10, 2018 / Notices
Washington, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–1019, tisha.washington@
fda.hhs.gov no later than September 4,
2018.
Requests for Oral Presentations:
During online registration you may
indicate if you wish to present at the
public comment session, and which
topic(s) you wish to address. We will do
our best to accommodate requests to
make public comments. Individuals and
organizations with common interests are
urged to consolidate or coordinate their
presentations, and request time for a
joint presentation. Following the close
of registration, we will determine the
amount of time allotted to each
presenter and the approximate time
each oral presentation is to begin, and
will select and notify participants by
September 5, 2018. All requests to make
oral presentations must be received by
the close of registration on September 4,
2018. If selected for presentation, any
presentation materials must be emailed
to Tisha Washington (see FOR FURTHER
INFORMATION CONTACT) no later than
close of business, September 6, 2018. No
commercial or promotional material
will be permitted to be presented or
distributed at the public workshop.
Streaming Webcast of the Public
Workshop: This public workshop will
also be webcast. The webcast link will
be available on the following web page
5 days before the workshop at: https://
www.fda.gov/Drugs/NewsEvents/
ucm611203.htm.
If you have never attended a Connect
Pro event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. FDA has
verified the website addresses in this
document, as of the date this document
publishes in the Federal Register, but
websites are subject to change over time.
Transcripts: Please be advised that as
soon as a transcript of the public
workshop is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Dockets Management Staff (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852. A link to the transcript will
also be available on the internet at
https://www.fda.gov/Drugs/NewsEvents/
ucm611203.htm.
VerDate Sep<11>2014
19:03 Aug 09, 2018
Jkt 244001
Dated: August 6, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–17130 Filed 8–9–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
HHS Approval of Entities That Certify
Medical Review Officers
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
This notice publishes a list of
the Department of Health and Human
Services (HHS) approved Medical
Review Officers certification entities.
The HHS Mandatory Guidelines for
Federal Workplace Drug Testing
Programs (Mandatory Guidelines),
applicable on October 1, 2017,
addresses the role and qualifications of
Medical Review Officers (MROs) and
HHS approval of entities that certify
MROs.
FOR FURTHER INFORMATION CONTACT:
Sean J. Belouin, Pharm.D., CAPT,
United States Public Health Service,
Senior Pharmacology and Regulatory
Policy Advisor, Substance Abuse and
Mental Health Services Administration,
5600 Fishers Lane, Room 16N06D,
Rockville, Maryland 20857; Telephone:
(240) 276–2716; Email: sean.belouin@
samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION: Subpart
M—Medical Review Officer (MRO),
Section 13.2 of the Mandatory
Guidelines, ‘‘How are nationally
recognized entities or subspecialty
boards that certify MROs approved?’’
states as follows: ‘‘All nationally
recognized entities or subspecialty
boards which seek approval by the
Secretary to certify physicians as MROs
for federal workplace drug testing
programs must submit their
qualifications, a sample examination,
and other necessary supporting
examination materials (e.g., answers,
previous examination statistics or other
background examination information, if
requested) (OMB Control No.: 0930–
0158). Approval will be based on an
objective review of qualifications that
include a copy of the MRO applicant
application form, documentation that
the continuing education courses are
accredited by a professional
organization, and the delivery method
and content of the examination. Each
approved MRO certification entity must
SUMMARY:
PO 00000
Frm 00107
Fmt 4703
Sfmt 4703
39763
resubmit their qualifications for
approval every two years. The Secretary
shall publish at least every two years a
notice in the Federal Register listing
those entities and subspecialty boards
that have been approved. This notice is
also available on the internet at https://
www.samhsa.gov/workplace/drugtesting.’’
HHS has completed its review of
entities that certify MROs, in
accordance with requests submitted by
such entities to HHS.
The HHS Secretary approves the
following MRO certifying entities that
offer MRO certification through
examination:
American Association of Medical
Review Officers (AAMRO), P.O. Box
12873, Research Triangle Park, NC
27709, Phone: (919) 489–5407, Fax:
(919) 490–1010, Email: bbrandon@
aamro.com, website: https://
www.aamro.com/.
Medical Review Officer Certification
Council (MROCC), 3231 S. Halsted St,
#167, Chicago, IL 60608, Phone: (847)
631–0599, Fax: (847) 483–1282,
Email: mrocc@mrocc.org, website:
https://www.mrocc.org/.
DATES: HHS approval is effective July
31, 2018.
Alex M. Azar II,
Secretary.
[FR Doc. 2018–17184 Filed 8–9–18; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Alcohol Abuse and
Alcoholism.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
E:\FR\FM\10AUN1.SGM
10AUN1
]]>Agencies
[Federal Register Volume 83, Number 155 (Friday, August 10, 2018)]
[Notices]
[Page 39763]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-17184]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
HHS Approval of Entities That Certify Medical Review Officers
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice publishes a list of the Department of Health and
Human Services (HHS) approved Medical Review Officers certification
entities. The HHS Mandatory Guidelines for Federal Workplace Drug
Testing Programs (Mandatory Guidelines), applicable on October 1, 2017,
addresses the role and qualifications of Medical Review Officers (MROs)
and HHS approval of entities that certify MROs.
FOR FURTHER INFORMATION CONTACT: Sean J. Belouin, Pharm.D., CAPT,
United States Public Health Service, Senior Pharmacology and Regulatory
Policy Advisor, Substance Abuse and Mental Health Services
Administration, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland
20857; Telephone: (240) 276-2716; Email: [email protected].
SUPPLEMENTARY INFORMATION: Subpart M--Medical Review Officer (MRO),
Section 13.2 of the Mandatory Guidelines, ``How are nationally
recognized entities or subspecialty boards that certify MROs
approved?'' states as follows: ``All nationally recognized entities or
subspecialty boards which seek approval by the Secretary to certify
physicians as MROs for federal workplace drug testing programs must
submit their qualifications, a sample examination, and other necessary
supporting examination materials (e.g., answers, previous examination
statistics or other background examination information, if requested)
(OMB Control No.: 0930-0158). Approval will be based on an objective
review of qualifications that include a copy of the MRO applicant
application form, documentation that the continuing education courses
are accredited by a professional organization, and the delivery method
and content of the examination. Each approved MRO certification entity
must resubmit their qualifications for approval every two years. The
Secretary shall publish at least every two years a notice in the
Federal Register listing those entities and subspecialty boards that
have been approved. This notice is also available on the internet at
https://www.samhsa.gov/workplace/drug-testing.''
HHS has completed its review of entities that certify MROs, in
accordance with requests submitted by such entities to HHS.
The HHS Secretary approves the following MRO certifying entities
that offer MRO certification through examination:
American Association of Medical Review Officers (AAMRO), P.O. Box
12873, Research Triangle Park, NC 27709, Phone: (919) 489-5407, Fax:
(919) 490-1010, Email: [email protected], website: https://www.aamro.com/.
Medical Review Officer Certification Council (MROCC), 3231 S. Halsted
St, #167, Chicago, IL 60608, Phone: (847) 631-0599, Fax: (847) 483-
1282, Email: [email protected], website: https://www.mrocc.org/.
DATES: HHS approval is effective July 31, 2018.
Alex M. Azar II,
Secretary.
[FR Doc. 2018-17184 Filed 8-9-18; 8:45 am]
BILLING CODE 4162-20-P
